Literature DB >> 18678830

Four new cases of therapy-related acute promyelocytic leukemia after mitoxantrone.

I Bosca1, A M Pascual, B Casanova, F Coret, M A Sanz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18678830     DOI： 10.1212/01.wnl.0000324422.69067.e7

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  8 in total

1.  Manipulating DNA damage-response signaling for the treatment of immune-mediated diseases.

Authors:  Jonathan P McNally; Scott H Millen; Vandana Chaturvedi; Nora Lakes; Catherine E Terrell; Eileen E Elfers; Kaitlin R Carroll; Simon P Hogan; Paul R Andreassen; Julie Kanter; Carl E Allen; Michael M Henry; Jay N Greenberg; Stephan Ladisch; Michelle L Hermiston; Michael Joyce; David A Hildeman; Jonathan D Katz; Michael B Jordan
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-22       Impact factor: 11.205

Review 2.  The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.

Authors:  Gregory Heath; Archana Airody; Richard Peter Gale
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 3.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

Review 4.  Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Authors:  James J Marriott; Janis M Miyasaki; Gary Gronseth; Paul W O'Connor
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

5.  Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis.

Authors:  Syed Khizer Hasan; Ashley N Mays; Tiziana Ottone; Antonio Ledda; Giorgio La Nasa; Chiara Cattaneo; Erika Borlenghi; Lorella Melillo; Enrico Montefusco; José Cervera; Christopher Stephen; Gnanam Satchi; Anne Lennard; Marta Libura; Jo Ann W Byl; Neil Osheroff; Sergio Amadori; Carolyn A Felix; Maria Teresa Voso; Wolfgang R Sperr; Jordi Esteve; Miguel A Sanz; David Grimwade; Francesco Lo-Coco
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

6.  Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.

Authors:  Francesco Patti; Salvatore Lo Fermo
Journal:  Autoimmune Dis       Date:  2011-03-15

7.  Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.

Authors:  Carmen Alcalá; F Gascón; F Pérez-Miralles; S Gil-Perotín; A Navarré; I Boscá; F Coret; B Casanova
Journal:  J Neurol       Date:  2018-05-21       Impact factor: 6.682

8.  Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.

Authors:  Victor M Rivera; Douglas R Jeffery; Bianca Weinstock-Guttman; Daena Bock; Fernando Dangond
Journal:  BMC Neurol       Date:  2013-07-11       Impact factor: 2.474
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.